BALAXI PHARMACEUTICALS LIMITED — Others, 05-11-2024: Resignation

Balaxi Pharmaceuticals' Board has approved the unaudited financial results for Q2 FY2024. Revenues amounted to ₹211.55 crores, with a net profit of ₹16.61 crores. Mr. Mahesh Inani resigned as Company Secretary, effective November 5, 2024, while Mr. Mohith Kumar Khandelwal has been appointed to the role, effective November 6, 2024. The financial statements and related documents are available on the company's website.